217 related articles for article (PubMed ID: 30723874)
1. Combining Omalizumab with Another Biotherapy.
Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
[No Abstract] [Full Text] [Related]
2. Omalizumab therapy in a patient with cronic spontaneous urticaria, ulcerative colitis, hypereosinophilia and prurigo Besnier: a case report.
Grieco T; Chello C; Faina V; Gomes VV; Alei L; Sernicola A; Panasiti V; Calvieri S
J Dermatolog Treat; 2018; 29(sup3):10-13. PubMed ID: 30256692
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of omalizumab in severe chronic spontaneous urticaria: Real life data from a Greek tertiary center.
Kyriakou A; Trigoni A; Sotiriadis D; Patsatsi A
Dermatol Ther; 2018 Nov; 31(6):e12739. PubMed ID: 30194796
[No Abstract] [Full Text] [Related]
4. Efficacy of Omalizumab Treatment with Concomitant Antihistamines as Needed for Moderate, Refractory Chronic Spontaneous Urticaria.
Nettis E; Cegolon L; Macchia L; Zaza I; Calogiuri G; Di Leo E
Acta Derm Venereol; 2018 Apr; 98(4):446-448. PubMed ID: 29362811
[No Abstract] [Full Text] [Related]
5. Biologics in Chronic Urticaria.
Bulkhi A; Cooke AJ; Casale TB
Immunol Allergy Clin North Am; 2017 Feb; 37(1):95-112. PubMed ID: 27886913
[TBL] [Abstract][Full Text] [Related]
6. Angioedema is an unfavorable factor for the response to omalizumab in chronic spontaneous urticaria: A retrospective study.
Serarslan G; Uzun M; Doğramacı AÇ; Çelik E
Dermatol Ther; 2019 Jan; 32(1):e12752. PubMed ID: 30238582
[TBL] [Abstract][Full Text] [Related]
7. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.
Gericke J; Metz M; Ohanyan T; Weller K; Altrichter S; Skov PS; Falkencrone S; Brand J; Kromminga A; Hawro T; Church MK; Maurer M
J Allergy Clin Immunol; 2017 Mar; 139(3):1059-1061.e1. PubMed ID: 27838346
[No Abstract] [Full Text] [Related]
8. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
9. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria.
Straesser MD; Oliver E; Palacios T; Kyin T; Patrie J; Borish L; Saini SS; Lawrence MG
J Allergy Clin Immunol Pract; 2018; 6(4):1386-1388.e1. PubMed ID: 29175369
[No Abstract] [Full Text] [Related]
10. Real-life treatment of cholinergic urticaria with omalizumab.
Altrichter S; Chuamanochan M; Knoth H; Asady A; Ohanyan T; Metz M; Maurer M
J Allergy Clin Immunol; 2019 Feb; 143(2):788-791.e8. PubMed ID: 30312709
[No Abstract] [Full Text] [Related]
11. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis.
Karstarli Bakay OS; Kacar N
Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106
[No Abstract] [Full Text] [Related]
12. Omalizumab use during pregnancy for CIU: a tertiary care experience.
Cuervo-Pardo L; Barcena-Blanch M; Radojicic C
Eur Ann Allergy Clin Immunol; 2016 Jul; 48(4):145-6. PubMed ID: 27425170
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab-induced triphasic anaphylaxis in a patient with chronic spontaneous urticaria.
Gönül M; Özenergün Bittacı A; Ergin C
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):e135-e136. PubMed ID: 26446412
[No Abstract] [Full Text] [Related]
14. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
Syrigos N; Grapsa D; Syrigou E
Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of omalizumab in a patient with chronic urticaria and hepatitis C.
Leiva-Salinas M; Francés L; Marin-Cabanas I; Arribas Granados MP; Silvestre JF
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1027-8. PubMed ID: 24629127
[No Abstract] [Full Text] [Related]
17. Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria.
Koski R; Kennedy KK
Ann Allergy Asthma Immunol; 2017 Nov; 119(5):397-401. PubMed ID: 29150066
[No Abstract] [Full Text] [Related]
18. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
[TBL] [Abstract][Full Text] [Related]
19. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria.
Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV
Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427
[No Abstract] [Full Text] [Related]
20. Development of angio-oedema after omalizumab injections in a patient with chronic spontaneous urticaria.
Magen E; Chikovani T
Clin Exp Dermatol; 2018 Oct; 43(7):825. PubMed ID: 29777532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
